Evidence map›Paper›PMID 33669900›Full record

ArticlePharmaceuticals (Basel, Switzerland)2021

Α Multicenter Retrospective Study Evaluating Brivaracetam in the Treatment of Epilepsies in Clinical Practice.

Maria Stefanatou, Eirini Vasileiadou Kapetanou, Vasilios K Kimiskidis, Vasileios Papaliagkas, Panagiotis Polychronopoulos, Sofia Markoula, Kleoniki Charisiou, Dimitrios Kazis, Anastasia Verentzioti, Panayiotis Patrikelis and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Maria Stefanatou1st Department of Neurology, National and Kapodistrian University of Athens, 115 28 Athens, Greece.
Eirini Vasileiadou KapetanouDepartment of Applied Statistics, University of Piraeus, 185 34 Piraeus, Greece.ORCID 0000-0002-1639-2796
Vasilios K KimiskidisLaboratory of Clinical Neurophysiology, Aristotle University of Thessaloniki, 541 24 Thessaloniki, Greece.
Vasileios PapaliagkasLaboratory of Clinical Neurophysiology, Aristotle University of Thessaloniki, 541 24 Thessaloniki, Greece.ORCID 0000-0003-1064-0290
Panagiotis PolychronopoulosDepartment of Neurology, University of Patras, 254 04 Patras, Greece.
Sofia MarkoulaDepartment of Neurology, University Hospital of Ioannina, 451 10 Ioannina, Greece.
Kleoniki CharisiouDepartment of Neurology, University Hospital of Ioannina, 451 10 Ioannina, Greece.
Dimitrios Kazis3rd Department of Neurology, "G. Papanikolaou" Hospital, Aristotle University of Thessaloniki, 541 24 Thessaloniki, Greece.
Anastasia Verentzioti1st Department of Neurosurgery, "Evangelismos" Hospital, National and Kapodistrian University of Athens, 106 76 Athens, Greece.
Panayiotis Patrikelis1st Department of Neurosurgery, "Evangelismos" Hospital, National and Kapodistrian University of Athens, 106 76 Athens, Greece.
Athanasia Alexoudi1st Department of Neurosurgery, "Evangelismos" Hospital, National and Kapodistrian University of Athens, 106 76 Athens, Greece.
Stylianos Gatzonis1st Department of Neurosurgery, "Evangelismos" Hospital, National and Kapodistrian University of Athens, 106 76 Athens, Greece.
National and Kapodistrian University of Athens · GRAristotle University of Thessaloniki · GRUniversity Hospital of Ioannina · GRUniversity of Patras · GRUniversity of Piraeus · GR

Funding

UCB S.A. ELKE 14960
6 · The paper itself

Abstract

Brivaracetam (BRV) is the latest approved antiepileptic drug. The aim of the study was to evaluate the efficacy and tolerability of BRV in everyday clinical practice. In this retrospective, observational, multicenter study, data from epilepsy patients receiving BRV from January 2018 to July 2019 were analyzed. Patients with age ≥16 suffering from any type of epilepsy and having at least one follow up encounter after dose titration were included. 156 consecutive patients were included in the study. The mean age was 40 (16-84 years) and the mean duration of epilepsy was 21 years. Of the 156 patients, 81% were diagnosed with focal-onset seizures, 16% with generalized seizures, while 3% suffered from unclassified seizures. Nine patients received BRV as monotherapy as a switching therapy. At the first follow up visit, seizure cessation was achieved in 56 (36%) patients and the rate of ≥50% responders was 36%. Twenty four patients (15%) remained unchanged; six patients (4%) were recorded with increased seizure frequency, while the remaining 9% had a response of less than 50%

Indexed as

antiepileptic drugsbrivaracetamclinical practiceepilepsytreatment

Identifiers

PMID33669900
PMCPMC7923268
OpenAlexW3130937654

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.